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Natural killer (NK) cells of the innate immune system are cytotoxic lymphocytes that 
play an important roles following transplantation of solid organs and hematopoietic 
stem cells. Recognition of self-human leukocyte antigen (HLA) class I molecules by 
inhibitory killer cell immunoglobulin-like receptors (KIRs) is involved in the calibration of 
NK cell effector capacities during the developmental stage, allowing the subsequent 
recognition and elimination of target cells with decreased expression of self-HLA class 
I (due to virus infection or tumor transformation) or HLA class I disparities (in the setting 
of allogeneic transplantation). NK cells expressing an inhibitory KIR-binding self-HLA 
can be activated when confronted with allografts lacking a ligand for the inhibitory 
receptor. Following the response of the adaptive immune system, NK cells can further 
destroy allograft endothelium by antibody-dependent cell-mediated cytotoxicity 
(ADCC), triggered through cross-linking of the CD16 Fc receptor by donor-specific 
antibodies bound to allograft. Upon recognizing allogeneic target cells, NK cells also 
secrete cytokines and chemokines that drive maturation of dendritic cells to promote 
cellular and humoral adaptive immune responses against the allograft. The cumulative 
activating and inhibitory signals generated by ligation of the receptors regulates mature 
NK cell killing of target cells and their production of cytokines and chemokines. This 
review summarizes the role of NK cells in allograft rejection and proposes mechanistic 
concepts that indicate a prominent role for KIR–HLA interactions in facilitating NK 
cells for Fc receptor-mediated ADCC effector function involved in antibody-mediated 
rejection of solid organ transplants.
Keywords: antibody-mediated rejection, antibody-dependent cell-mediated cytotoxicity, human leukocyte 
antigen, killer cell immunoglobulin-like receptors, natural killer cells, donor-specific antibodies, solid organ 
transplantation, transplant rejection
FiGURe 1 | Mechanisms of donor-specific antibody-mediated 
rejection of renal allografts. Donor-specific HLA antibody binding to the 
allograft endothelium may trigger four distinct cellular and humoral 
mechanisms that could result in significant graft injury and failure: (1) 
activation of complement cascade can cause direct injury to the capillary 
endothelium, (2) antibody-dependent cell-mediated cytotoxicity by natural 
killer cells, (3) opsonization and increased antigen presentation, and (4) 
activation and proliferation of endothelial cell. FcR, Fc receptor; i-KIR, 
inhibitory KIR; a-KIR, activating KIR; APC, antigen-presenting cell; C1q, 
a complement complex.
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ANTiBODY-MeDiATeD ReJeCTiON OF 
ORGAN ALLOGRAFT
The major hurdle to successful organ transplantation is graft 
rejection, a process orchestrated by sophisticated cell and 
antibody-mediated defense mechanisms, which has evolved 
primarily to combat invading microbes or diseased and damaged 
cells. The T cell-targeted immunosuppressive regimens (includ-
ing T cell-specific antibodies, calcineurin inhibitors, mycophe-
nolic acid, rapamycin, and prednisone) have effectively reduced 
the incidence of cell-mediated transplant rejection and have 
substantially improved 1-year graft survival to 88% following 
renal transplantation (1). Nevertheless, alloantibodies mediate a 
substantial proportion of the remaining graft rejection episodes, 
contributing to both early and late graft loss, particularly in 
sensitized populations such as patients with previous transplants 
and patients who have previously had multiple pregnancies or 
multiple blood transfusions (2).
Antibody-mediated rejection (ABMR) is recognized to be a 
key problem in organ transplantation and a major cause of late 
graft loss (3). Based on time course, the ABMR is classified as 
hyperacute, acute, or chronic (1). Hyperacute rejection, the first 
rejection phenotype observed in human organ transplantation, 
occurs immediately on perfusion of the transplanted organ 
with the blood of the recipient (4). Preformed donor-specific 
antibodies (DSAs) in recipient’s blood bind to antigens expressed 
on vascular endothelium of the transplanted allograft [such as 
human leukocyte antigens (HLAs), ABO blood group antigens, 
and other endothelial antigens] and trigger a cascade of comple-
ment activation, which results in tissue injury involving blood 
vessel wall damage, hemorrhage, neutrophil infiltration, platelet, 
and fibrin deposition. Reliable cross-matching methods and 
screening recipients for preformed circulating HLA antibodies 
to the prospective donor have almost eliminated the incidence of 
this devastating phenotype (5, 6).
Acute ABMR occurs at any time from days to years following 
transplantation, and results from DSA that may be preexisting or 
develop de novo after transplantation (7). At present, acute ABMR 
is defined by four criteria: clinical evidence of acute graft dysfunc-
tion, histologic evidence of acute tissue injury, immunohistologic 
evidence for the action of DSAs (C4d deposition in peritubular 
capillaries), and DSAs detected in the serum (8). ABMR occurs in 
6.7% of renal transplant patients and is present in approximately 
one-third of renal transplant patients diagnosed with acute 
rejection (9–11). Acute ABMR is characterized by a rapid rise 
in serum creatinine and is resistant to therapy with steroids or 
T cell-specific reagents.
Chronic ABMR develops over months or years before there 
are signs of graft dysfunction and is mediated by antibodies 
that develop de novo. The features of chronic ABMR in renal 
allografts include the following: duplication of the glomerular 
basement membrane, intimal cell proliferation of arterioles 
and infiltration with mononuclear cells, and lamination of 
the peritubular capillary basement membrane, which occurs 
together with the deposition of C4d in peritubular capillaries 
and glomeruli. Chronic ABMR is the result of cumulative dam-
age to the kidney and over 50% of recipients develop chronic 
ABMR at 10 years after transplantation (12). A further category 
of rejection, subclinical rejection, has recently been recognized, 
and this refers to pathological injury in the graft that has been 
caused by antibody and/or T cells, but which has not yet resulted 
in graft dysfunction.
MeCHANiSMS iNvOLveD iN ANTiBODY-
MeDiATeD ReJeCTiON OF ORGAN 
ALLOGRAFT
The Y-shaped structure of IgG antibodies provides a bifunctional 
capacity to initiate and regulate host defense mechanisms in 
the following ways: antigen binding through the Fab (antigen- 
binding fragment) portion of the antibody and the interaction 
with immune cells and complement proteins (fragment crystal-
lizable or Fc). Following DSA binding to the allograft endothe-
lium, at least four distinct cellular and humoral mechanisms exert 
significant graft injury and failure (Figure 1).
Activation of the Complement Cascade
Complement fixation by antibody is essential for the pathogen-
esis of acute and hyperacute rejection (13). The binding of DSA 
to a cell surface antigen expressed on the allograft may trigger 
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the classical complement pathway, a component of the innate 
immune system (14). The complement component C1q binds to 
structures in two or more Fc domains of IgM or IgG, which causes 
C1q to undergo a conformational change, which allows the enzy-
matic components C1r and C1s in the collagenous portion of the 
antibody-bound C1q to cleave C4 molecules (13). This initiation 
step then leads to the recruitment of other proteins in order to 
form the C3 convertase protein complex. Activation of C3 leads 
to the generation of two pro-inflammatory anaphylatoxins, C3a 
and C5a, and the membrane attack complex that eventually 
forms a pore in the membrane of the target and induces cell 
death. The classical pathway is only one of three methods of 
complement activation, the others being the alternative pathway 
and the lectin pathway, and all three pathways converge at the 
point of C3 cleavage (13). C4d is a split product of C4 groups, 
which remains covalently bound to the tissue and is thereby a 
durable in  situ marker of complement activation. Detection of 
C4d deposition in capillaries has proved to be the most reliable 
marker of ABMR (15). Although the peritubular capillary C4d 
detection is important, it is not necessary to diagnosis ABMR, 
since the presence of DSA has the potential to cause transplant 
glomerulopathy and graft loss due to complement-independent 
mechanisms (16).
Antibody-Dependent Cell-Mediated 
Cytotoxicity
In addition to activating complement-dependent cytotoxicity 
against the allograft, antibodies can mount immune responses 
through interacting with Fc receptors (FcγRs), which are widely 
expressed throughout the hematopoietic system (17). Three dif-
ferent classes of FcγRs, known as FcγRI (CD64), FcγRII (CD32) 
with A, B, and C isoforms, and FcγRIII (CD16) with A and B 
isoforms, have been recognized in humans. Except FcγRIIIB that 
is present mainly on neutrophils, all other FcγRs are activating 
receptors. Innate immune effector cells, including monocytes, 
macrophages, dendritic cells (DCs), basophils, and mast cells, 
coexpress activating and inhibitory FcγRs, whereas B-cells 
express the inhibitory receptor FcγRIIB (17). Natural killer (NK) 
cells, particularly those with CD56dim CD16+ phenotype express 
activating low-affinity FcγRIIIA. NK cells are regarded as the 
key effector cells mediating antibody-dependent cell-mediated 
cytotoxicity (ADCC) function since NK cells are the only subset 
that do not coexpress the inhibitory FcγRIIB (18).
Infiltration of recipient NK cells into the renal (19), cardiac 
(20), lung (21), and liver (22) allografts shortly following trans-
plantation have been observed indicating a role for human NK 
cells in solid organ transplantation. Direct evidence for the role 
of NK cells in microcirculation injury during ABMR comes from 
the findings of NK cells and NK cell transcripts in kidney biop-
sies from patients with donor-specific HLA antibodies (23, 24). 
Mechanistic studies confirming the role of DSA-dependent NK 
cell-mediated cytotoxicity in organ allograft rejections is lacking 
(25). However, clinical trials with cancer therapeutic antibod-
ies have shown that the induction of NK cell-mediated ADCC 
have direct bearing on organ allograft rejection. For example, 
rituximab, a chimeric mouse-human IgG1 monoclonal antibody 
that recognizes the CD20 antigen expressed on mature B-cells, is 
used to treat patients with B-cell lymphomas and autoimmune 
disorders. Both quantitative and qualitative differences in NK 
cell function are correlated with rituximab clinical activity, sug-
gesting that ADCC performed by NK cells may be a primary 
mechanism of rituximab activity (26). Furthermore, responses 
to rituximab may depend on polymorphisms present in the 
FcRIIIA receptor, a receptor mainly expressed on NK cells (27, 
28). Several other antibodies are currently being evaluated in the 
clinic and, for many of them, their effect seems to be mediated 
at least in part by NK cell-mediated ADCC (29). In addition to 
ADCC, on FcγRIIIA stimulation, NK cells produce cytokines 
and chemokines, including interferon-γ (IFN-γ), which may 
induce HLA expression on endothelial cells, thus providing more 
antigenic targets for antibodies and shortening graft survival 
(30). More understanding of FcγRIIIA-mediated regulation of 
NK cell function is critical in order to define the role of NK cell 
transcripts in kidney biopsies from patients with donor-specific 
HLA antibodies.
Opsonization and Promotion of Antigen 
Presentation
In addition to their well-defined roles in triggering ADCC by 
NK cells, FcγRs regulate antigen presentation, immune complex-
mediated maturation of DCs, B cell activation, and plasma cell 
survival, and therefore, FcγRs ultimately regulate the production 
and specificity of their ligands, antibodies (31). The ligation of 
Fab of the DSA to the alloantigen attracts phagocytes (neutro-
phils, monocytes, macrophages, and DCs) to infiltrate into the 
allograft. The Fc fragment of the antibody binds to an Fc receptor 
on the phagocyte, facilitating receptor-mediated phagocytosis, 
which accelerates the kinetics of the phagocytosis process (32). 
Phagocytosis initiates specific mechanisms that result in traffick-
ing of the antigen–IgG immune complexes into compartments 
from which the antigens are processed into peptides for HLA class 
I and class II presentation to CD8+ and CD4+ T cells, respectively, 
thereby FcγRs bridge the humoral and cellular branches of the 
adaptive immune response.
Activation of endothelial Cells
The in  vitro experiments of anti-HLA antibody ligation have 
shown that HLA class I molecules expressed by endothelial cells 
stimulates endothelial cell activation and proliferation (33, 34). 
Endothelial cell proliferation may be at least partly causative 
of arterial intimal thickening that is characteristics of chronic 
allograft rejection.
NATURAL KiLLeR CeLLS LiNK iNNATe 
AND ADAPTive iMMUNiTY
Natural killer cells are the third population of lymphocytes 
defined by the CD3− CD56+ cell surface phenotype, and they 
represent 5–25% of the mononuclear cell fraction of normal 
human peripheral blood (35). NK cells share several features 
with CD8+ cytolytic T-lymphocytes in their development, 
morphology, cell surface phenotypes, killing mechanism, and 
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cytokine production (36). NK cells were originally described 
as innate lymphocytes capable of lysing target cells quickly by 
direct cytotoxicity in an antigen-independent manner without 
the “priming” period required by T-cells (37). NK cells are 
recognized to express a sophisticated repertoire of activating and 
inhibitory receptors that are calibrated to ensure self-tolerance, 
while exerting early assaults against virus infection (38) and 
tumor transformation (39). In addition to cytolytic functions, 
NK cells produce high levels of IFN-γ and a wide range of 
pro-inflammatory cytokines and chemokines, which contribute 
to the shaping of adaptive immune responses (40). Recently, NK 
cells have been shown to mount antigen-specific immunologic 
memory, a hallmark characteristic of adaptive immunity (41). 
Having properties of both innate and adaptive immunity, NK 
cells spontaneously lyse target cells, as well as function as 
regulatory cells influencing subsequent antigen-specific T-cell 
and B-cell responses.
NK CeLLS iN SOLiD ORGAN 
TRANSPLANTATiON
Experiments with rodent models clearly indicate a role for 
NK cells in acute and chronic allograft rejection (42–44). The 
most convincing evidence of NK cell-mediated rejection was 
observed with the heart allograft missing-self-MHC class I 
in CD28-deficient recipient mice; in this model, rejection is 
prevented by depletion of host NK cells (45). NK cells play 
a crucial role in mediating long-term kidney allograft injury 
(46). Currently, used clinical regimen of immunosuppressive 
agents such as cyclosporine A (47), FK506 (48), mycophenolate 
mofetil (49), azathioprine (50), and rapamycin (51) appears 
not to abrogate NK cell function. NK cell number and the 
cytotoxicity function were preserved to a greater extent in a 
regimen of tacrolimus and mycophenolate mofetil than they 
were with cyclosporine A and azathioprine 12  months after 
kidney transplantation (52). Even in the presence of polyclonal 
anti-thymoglobuline antibody that depleted T and NK cells 
transiently, the NK cell effector function is preserved after 
kidney transplantation (53).
NK CeLLS USe A COMPLeX ReCePTOR–
LiGAND SYSTeM TO DiSTiNGUiSH  
NON-SeLF FROM THe SeLF
Natural killer cells use very complex and specific receptor– 
ligand system that integrates signals triggered by an array of 
inhibitory and activating receptors, which trigger cytotoxic-
ity and the secretion of chemokines and cytokines (54, 55). 
Unlike T- and B-lymphocytes, NK cells do not express recep-
tors that require somatic gene rearrangements to generate 
receptor diversity and specificity. Instead, NK cells express 
a wide array of conventional germline-encoded receptor 
families with inhibitory or activating functions that scan for 
missing-self, induced-self, and altered-self on target cells. The 
well-characterized NK cell receptor gene families include killer 
cell immunoglobulin-like receptors (KIR), killer cell lectin-like 
receptors, leukocyte immunoglobulin-like receptors, and 
 natural cytotoxicity  receptors (56–59).
KiLLeR CeLL iMMUNOGLOBULiN-LiKe 
ReCePTORS AND HLA CLASS i LiGANDS
The KIRs are crucial for human NK cell development and func-
tion (56, 58, 60) (Figure 2). The KIR gene family does not exist 
in rodents and found only in primates, and therefore KIR genes 
are considered to be originated recently and evolved rapidly 
(61, 62). The KIR gene family consists of 16 highly homologous 
genes clustered at the leukocyte receptor complex on chromo-
some 19 (63, 64) (Figure 3). Seven of them encode inhibitory 
KIRs (3DL1–3, 2DL1–3, and 2DL5), six encode activating KIRs 
(3DS1, 2DS1–2DS5), one encode a KIR that can trigger both 
inhibitory and activating signals (2DL4), and two are pseudo-
genes (2DP1 and 3DP1) that do not encode a cell surface recep-
tor. By recognizing specific HLA class I ligands, the inhibitory 
KIRs trigger signals that stop NK cell function, while the ligands 
for activating KIRs are not elucidated. Genetic association stud-
ies suggest the possibility of activating KIRs recognizing cell 
surface determinants expressed following infection or tumor 
transformation, or under certain physiological, stress such as 
transplantation (65).
In general, humans have two copies of each autosomal gene, 
one per chromosome. However, due to deletion and duplica-
tion, the basic diploid rule does not apply to KIR gene family. 
The number and type of KIR genes vary substantially between 
haplotypes, and all KIR genes display sequence polymorphism 
(66) (Figure  3). On the basis of gene content, KIR haplotypes 
are broadly classified into two groups (67). Group A haplotypes 
have a fixed gene content (KIR3DL3–2DL3–2DP1–2DL1–3DP1–
2DL4–3DL1–2DS4–3DL2) that encode four inhibitory KIRs, 
2DL1, 2DL3, 3DL1, and 3DL2, specific for four major HLA class I 
ligands, C2, C1, Bw4, and A3/A11, respectively, and an activating 
KIR 2DS4, which is weakly specific for some HLA-C allotypes 
(C1 or C2 epitope), as well as the HLA-A3/11 epitope (Figure 2). 
In contrast, group B haplotypes are variable both in numbers and 
combinations of KIR genes, and comprising several genes (2DL2, 
2DL5, 2DS1, 2DS2, 2DS3, 2DS5, and 3DS1) that are not part of 
the A haplotype (63, 68, 69). Moreover, B haplotypes possess KIRs 
that have no binding to HLA class I ligands, such as KIR2DL5, 
2DS2, 2DS3, and 2DS5. While group A haplotypes contain only 
KIR2DS4 as an activating gene, group B haplotypes contain up 
to five activating KIRs – KIR2DS1, 2DS2, 2DS3, 2DS5, and 3DS1. 
Inheritance of paternal and maternal haplotypes comprising 
different KIR gene contents generates human diversity in KIR 
genotypes (70). For example, homozygotes for group A haplo-
types have only seven functional KIR genes, while the heterozy-
gotes for group A and certain group B haplotypes may have all 14 
functional KIR genes. All human populations have both group 
A and B KIR haplotypes, but their incidences vary substantially 
among populations (71–74). The A and B haplotypes are equally 
distributed in Africans and Caucasians, while the A haplotype 
is overrepresented in Northeast Asians (Chinese, Japanese, and 
Koreans) and the B haplotype occurred most frequently in the 
indigenous populations of India, Australia, and America (75).
FiGURe 2 | Killer cell immunoglobulin-like receptor (KiR) and human leukocyte antigen (HLA) class i ligands. Fourteen distinct KIRs have been 
characterized in humans that comprise either 2 or 3 (2D or 3D) Ig-like domains and either a long (L) or short (S) cytoplasmic tail. Six KIRs are activating types and 
the remaining KIRs are inhibitory types. The cytoplasmic tails of the inhibitory KIRs carry an ITIM motif (shown as blue boxes) that trigger inhibitory signals upon 
binding to distinct HLA class I ligands. The short-tailed activating KIRs lack ITIM, but carry a positively charged amino acid residue in the transmembrane region 
(shown by yellow circle with + mark) that allows the interaction with an adopter chain DAP-12. The DAP12 contains ITAM motifs (shown as red boxes), which trigger 
activating signals upon the short-tailed KIR bound to a relevant ligand.
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NK CeLLS USe THRee DiSTiNCT 
MeCHANiSMS TO iNJURe ALLOGRAFT 
TiSSUe
The recipient NK cells can recognize and respond against the 
allograft by three possible mechanisms: missing-self recogni-
tion, induced-self recognition, and ADCC (Figure  4) (76). 
Because NK cells circulate in a state that can spontaneously 
deliver effector function, it is critical that they do not attack 
surrounding healthy cells. To prevent such detrimental auto-
reactivity, NK cells express an array of inhibitory receptors 
recognizing self-HLA class I molecules (Figure 4A). Expression 
of four distinct HLA class I molecules (HLA-A, -B, -C, and -E) 
on normal healthy cells provides ligands for various inhibitory 
receptors of NK cells and, consequently, are resistant to NK 
cell attack. Downregulation of HLA class I expression due to 
certain viral infections, neoplastic transformations, or absence 
of relevant HLA class I ligands on the allograft at the setting of 
allogeneic transplantation, alleviates inhibitory signals, permit-
ting NK cells to eliminate these unhealthy or allogeneic target 
cells, a phenomenon originally described as the “missing-self ” 
hypothesis (77) (Figure 4B, i). In addition to the “missing-self ” 
mechanism, the expression of ligands for activating receptors 
on stressed target cell surface might also contribute to NK cell 
attack, known as “induced-self ” recognition (Figure  4B, ii). 
The activation receptors can directly recognize stress-induced 
ligands associated with certain physiological conditions, such 
as infection, tumor transformation, and transplanted allograft 
(58, 78). The third mechanism is mediated via an ADCC 
(Figure  4B, iii), in which NK cells are activated through the 
low-affinity Fc receptor for IgG FcγRIIIA (CD16) by binding to 
the Fc portion of DSA. In summary, the NK cells discriminate 
the stressed unhealthy cells or allograft from the healthy self 
by gauging the net input of activating and inhibitory signals 
perceived from the NK cell receptors upon their interactions 
with target cell ligands.
FiGURe 4 | Natural killer (NK) cells distinguish allograft lacking self-human leukocyte antigen (HLA) class i molecules. The net signal integrated from the 
inhibitory and activating receptors determines the effector function of NK cells. NK cells spare healthy cells that express high levels of HLA class I molecules and low 
levels of ligands for activating receptors (A). Recognition of cognate HLA class I ligands on a healthy cell by inhibitory receptors expressed by NK cells prevents lysis 
of the healthy cell (A). NK cells recognize and injure allograft that has either disparate HLA class I (i. missing-self; loss of inhibition), express high levels of ligands for 
activating receptors (ii. induced-self; dominant activation), and/or iii. donor-specific HLA antibody-dependent cell-mediated cytotoxicity (B). FcR, Fc receptor; i-KIR, 
inhibitory KIR; a-KIR, activating KIR; DSAs, donor-specific antibodies.
FiGURe 3 | Killer cell immunoglobulin-like receptor (KiR) haplotypes vary in gene content. Map of common KIR haplotypes in Caucasian populations. Each 
box represents a KIR gene. Haplotype#1 represents group-A KIR haplotype and the remainder are group-B haplotypes. The framework (Fw) genes, present in all 
haplotypes are shown in gray; genes encoding activating KIR are in pink (A haplotype-specific) or red/orange (B haplotype-specific); those for inhibitory receptors are 
in purple (A haplotype-specific) or blue (B haplotype-specific); and Pseudogene (Ps) 2DP1 is in white. All KIR genes are polymorphic, and the number of alleles and 
proteins characterized for each KIR gene is indicated.
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CLONAL eXPReSSiON OF KiR AND 
ACQUiSiTiON OF NK CeLL TOLeRANCe 
AND ReSPONSiveNeSS
Similar to T- and B-lymphocytes, NK cells are developed from 
CD34+ hematopoietic stem cells in the bone marrow and undergo 
terminal maturation in secondary lymphoid tissues (79–81). A 
signature feature of KIR is their clonal expression on NK cells, so 
that each NK cell clone in a person expresses only a portion of the 
genes within their KIR genotype (82–84). Stochastic expression 
of different combinations of receptors by NK cells results in this 
repertoire of NK clones with various ligand specificities. Once a 
given KIR is expressed on an NK cell clone, it is maintained in a 
stable way in the progeny of the clone. The process that establishes 
these clonal patterns is based on epigenetic regulation by DNA 
methylation and histone modifications (85–87).
Because KIR and HLA genes are located on different chromo-
somes (KIR on chromosome 19 and HLA on chromosome 6), 
KIR genes are inherited independently from HLA genes, and 
KIR may be expressed in the absence of their HLA ligands (88). 
Most, but not all, NK cell clones in peripheral blood express at 
least one inhibitory receptor for self-HLA class I (82). Only those 
NK cell clones expressing at least one inhibitory KIR specific for 
self-HLA class I molecule are “licensed,” or functionally active, 
to eliminate target cells that have downregulated or which are 
missing the respective HLA class I ligands (74, 78, 89–91). 
A conceivable explanation for NK cell licensing is that inhibitory 
KIRs, upon specific interaction with self-HLA class I allotypes, 
deliver a signal resulting in NK cell maturation and acquisition 
of effector function. NK cells lacking inhibitory receptors for 
self-HLA class I molecules are considered to be developmentally 
immature, “unlicensed,” and substantially hyporesponsive to 
HLA class I-negative targets (74, 89, 92, 93). Therefore, the NK 
cell responsiveness is most fundamentally distinguished by the 
presence or lack of inhibitory KIR for self-HLA class I. Licensed 
NK cells further vary in effector function quantitatively according 
to the strength of the inhibitory KIR and HLA interactions and 
the copy number of the corresponding inhibitory KIR and HLA 
genes (94–96). In summary, KIR receptor–HLA class I ligand 
interactions at the developmental stage set the functional thresh-
old for NK cell and regulate NK cell effector function.
KiR–HLA iNTeRACTiONS CAN 
MODULATe THe DSA-DePeNDeNT 
NK CeLL-MeDiATeD CYTOTOXiCiTY 
AGAiNST ORGAN ALLOGRAFT
Polymorphic variation among the KIR and HLA class I genes 
and their resulting impact on the KIR and HLA interaction 
constitute a major source of variability in NK cell responsive-
ness (94–96). These differences influence clinical outcomes in 
diverse settings, including monoclonal antibody therapy for 
lymphoma (97), transplantation for hematological malignancies 
(98), kidney transplantation (99, 100), and other settings in which 
NK cell involvement contributes to disease control and clinical 
responses (101–105). However, not all KIR+ licensed NK cells are 
equivalent, as polymorphic diversity in the KIR and HLA genes 
underlie significant variation in binding strength and specific-
ity, which quantitatively influence licensing, inhabitability, and 
ADCC (104, 106–111).
However, studies supporting a role for licensing in human 
ADCC are limited. A prominent role for KIR3DL1/HLA-Bw4 
interactions in licensing NK cells for CD16-mediated effec-
tor function was published recently (112). When individuals 
expressed both inhibitory KIRs that interact with HLA-C and 
the corresponding HLA-C ligand, their NK cells exhibited greater 
general and Fc receptor-mediated effector functions than NK 
cells from those individuals lacking the relevant HLA-C ligand 
(74). Similarly, expression of KIR3DL1, an inhibitory KIR that 
interacts with the HLA-Bw4 public epitope, was associated with 
higher NK cell cytotoxicity and IFN-γ production upon exposure 
to HLA class I-deficient target cells when the NK cells were isolated 
from HLA-Bw4 donors (94, 112). Therefore, the interindividual 
differences in compound KIR and HLA class I ligand genotypes 
associated with differences in NK cell reactivity would impact 
DSA-mediated NK cell ADCC against the organ allograft. The 
individualized assessment of the recipient’s KIR, FcR, HLA types, 
HLA antibodies, and the donor’s HLA types at the molecular 
and functional levels have the potential to distinguish between 
mechanisms that could guide identification of new therapeutic 
targets for ABMR.
CONCLUDiNG ReMARKS
The complement-independent mechanisms that lead to the 
ABMR of kidney allografts remain poorly understood. Recent 
studies finding a link between ABMR and abundance of NK cell 
molecular signatures in transplant biopsy suggest relevance of NK 
cells as innate immune cytotoxic effectors to antibodies through 
ADCC. However, the direct pathogenic role of donor-specific 
HLA antibody-mediated NK cytotoxicy in transplant rejection 
remains poorly documented by mechanistic studies. NK cells use 
very complex and specific germline-encoded KIR receptor and 
HLA class I ligand system that integrate signals triggered by an 
array of inhibitory and activating receptors, which set NK cell 
maturation and acquisition of effector function. Moreover, the 
FcγRIIIA polymorphisms and expression levels can also modulate 
NK cell activation against allograft. Future studies that integrate 
both recipient factors (such as KIR receptors, HLA class I ligands, 
FcγRIIIA polymorphisms, and donor-specific HLA antibodies) 
and donor factors (such as HLA class I ligand compatibility with 
recipient) that establish variable KIR–HLA conditioned NK cell-
FcγRIIIA-antibody–antigen interactions will identify potential 
interindividual variability of humoral alloimmune responses.
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